Mesothelioma B005

Current RMA Instruments:

Reasonable Hypothesis SOP

41 of 2024

Balance of Probabilities SOP

42 of 2024

Changes from Previous Instruments:

 

ICD coding:

Pleural (ICD-10 C45.0)

Pericardium (ICD-10 C45.2)

Peritoneum (ICD-10 C45.1)

Brief description:

Mesothelioma is a primary malignant neoplasm that is rare, aggressive and life-threatening. It is a cancer involving the mesothelial cells of the body, which line closed potential spaces of the body including the pleura (most common), pericardium, peritoneum and the tunica vaginalis of the testis.  

Confirming the diagnosis:

A biopsy of the malignancy is obtained with histological and immunochemical analysis undertaken to confirm this diagnosis. 

The relevant medical specialist is a medical oncologist or a respiratory physician.

Conditions not covered by these SOPs   

  • Soft tissue sarcoma*
  • Hodgkin’s lymphoma*
  • Non Hodgkin’s lymphoma*
  • Carcinoid tumour *

* another SOP applies  - the SOP has the same name unless otherwise specified

# non-SOP condition

Clinical onset

Assessing the date of clinical onset requires first confirming the established diagnosis via analysis of tissue samples and appropriate test results. The clinical date of onset can then be taken further back, if possible, to the first presentation of symptoms and signs consistent with the neoplasm. For example, if the case involves pleural mesothelioma, the symptoms can include chest pain, shortness of breath, persistent cough, weight loss and signs of enlarged lymph nodes. It usually will present in adults aged over 50 years old. 

Clinical worsening

For there to be an aggravation or situation involving clinical worsening, there needs to be clear progression of the condition out of keeping with the natural history expected of the underlying pathology.  Mesothelioma is usually associated with a poor prognosis and survival rate. Inability to obtain appropriate clinical management is unlikely to be relevant.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/sops-grouped-icd-body-system/m/mesothelioma-b005-c45

Last amended

Rulebase for mesothelioma

<div><p><strong>Current RMA Instruments:</strong></p><table border="1" cellpadding="1" cellspacing="1"><tbody><tr><td><address><p><a href="http://www.rma.gov.au/assets/SOP/2024/9000e4ad28/041.pdf&quot; target="_blank">Reasonable Hypothesis SOP</a></p></address></td><td>41 of 2024</td></tr><tr><td><address><p><a href="http://www.rma.gov.au/assets/SOP/2024/910bb94427/042.pdf&quot; target="_blank">Balance of Probabilities SOP</a></p></address></td><td>42 of 2024</td></tr></tbody></table><p><strong>Changes from Previous Instruments:</strong></p><drupal-media data-entity-type="media" data-entity-uuid="1bcf3714-89f1-42ae-bb67-8dc98d5a8bcc"> </drupal-media><p> </p><p><strong>ICD coding:</strong></p><p>Pleural (ICD-10 C45.0)</p><p>Pericardium (ICD-10 C45.2)</p><p>Peritoneum (ICD-10 C45.1)</p><p><strong>Brief description:</strong></p><p>Mesothelioma is a primary malignant neoplasm that is rare, aggressive and life-threatening. It is a cancer involving the mesothelial cells of the body, which line closed potential spaces of the body including the pleura (most common), pericardium, peritoneum and the tunica vaginalis of the testis.  <span><o:p></o:p></span></p><p><strong>Confirming the diagnosis:</strong></p><p>A biopsy of the malignancy is obtained with histological and immunochemical analysis undertaken to confirm this diagnosis. </p><p>The relevant medical specialist is a medical oncologist or a respiratory physician.</p><p><strong>Conditions not covered by these SOPs   </strong></p><ul><li>Soft tissue sarcoma*</li><li>Hodgkin’s lymphoma*</li><li>Non Hodgkin’s lymphoma*</li><li>Carcinoid tumour *</li></ul><p>* another SOP applies  - the SOP has the same name unless otherwise specified</p><p># non-SOP condition</p><p><strong>Clinical onset</strong></p><p>Assessing the date of clinical onset requires first confirming the established diagnosis via analysis of tissue samples and appropriate test results. The clinical date of onset can then be taken further back, if possible, to the first presentation of symptoms and signs consistent with the neoplasm. For example, if the case involves pleural mesothelioma, the symptoms can include chest pain, shortness of breath, persistent cough, weight loss and signs of enlarged lymph nodes. It usually will present in adults aged over 50 years old. </p><p><strong>Clinical worsening</strong></p><p>For there to be an aggravation or situation involving clinical worsening, there needs to be clear progression of the condition out of keeping with the natural history expected of the underlying pathology.  Mesothelioma is usually associated with a poor prognosis and survival rate. Inability to obtain appropriate clinical management is unlikely to be relevant.</p></div>

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/rulebase-mesothelioma

Asbestosis

Current RMA Instruments:

Reasonable Hypothesis SOP

41 of 2024

Balance of Probabilities SOP

42 of 2024

Changes from Previous Instruments:

 

ICD coding:

Pleural (ICD-10 C45.0)

Pericardium (ICD-10 C45.2)

Peritoneum (ICD-10 C45.1)

Brief description:

Mesothelioma is a primary malignant neoplasm that is rare, aggressive and life-threatening. It is a cancer involving the mesothelial cells of the body, which line closed potential spaces of the body including the pleura (most common), pericardium, peritoneum and the tunica vaginalis of the testis.  

Confirming the diagnosis:

A biopsy of the malignancy is obtained with histological and immunochemical analysis undertaken to confirm this diagnosis. 

The relevant medical specialist is a medical oncologist or a respiratory physician.

Conditions not covered by these SOPs   

  • Soft tissue sarcoma*
  • Hodgkin’s lymphoma*
  • Non Hodgkin’s lymphoma*
  • Carcinoid tumour *

* another SOP applies  - the SOP has the same name unless otherwise specified

# non-SOP condition

Clinical onset

Assessing the date of clinical onset requires first confirming the established diagnosis via analysis of tissue samples and appropriate test results. The clinical date of onset can then be taken further back, if possible, to the first presentation of symptoms and signs consistent with the neoplasm. For example, if the case involves pleural mesothelioma, the symptoms can include chest pain, shortness of breath, persistent cough, weight loss and signs of enlarged lymph nodes. It usually will present in adults aged over 50 years old. 

Clinical worsening

For there to be an aggravation or situation involving clinical worsening, there needs to be clear progression of the condition out of keeping with the natural history expected of the underlying pathology.  Mesothelioma is usually associated with a poor prognosis and survival rate. Inability to obtain appropriate clinical management is unlikely to be relevant.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/mesothelioma-b005-c45/rulebase-mesothelioma/asbestosis

Inability to obtain appropriate clinical management for mesothelioma

Current RMA Instruments:

Reasonable Hypothesis SOP

41 of 2024

Balance of Probabilities SOP

42 of 2024

Changes from Previous Instruments:

 

ICD coding:

Pleural (ICD-10 C45.0)

Pericardium (ICD-10 C45.2)

Peritoneum (ICD-10 C45.1)

Brief description:

Mesothelioma is a primary malignant neoplasm that is rare, aggressive and life-threatening. It is a cancer involving the mesothelial cells of the body, which line closed potential spaces of the body including the pleura (most common), pericardium, peritoneum and the tunica vaginalis of the testis.  

Confirming the diagnosis:

A biopsy of the malignancy is obtained with histological and immunochemical analysis undertaken to confirm this diagnosis. 

The relevant medical specialist is a medical oncologist or a respiratory physician.

Conditions not covered by these SOPs   

  • Soft tissue sarcoma*
  • Hodgkin’s lymphoma*
  • Non Hodgkin’s lymphoma*
  • Carcinoid tumour *

* another SOP applies  - the SOP has the same name unless otherwise specified

# non-SOP condition

Clinical onset

Assessing the date of clinical onset requires first confirming the established diagnosis via analysis of tissue samples and appropriate test results. The clinical date of onset can then be taken further back, if possible, to the first presentation of symptoms and signs consistent with the neoplasm. For example, if the case involves pleural mesothelioma, the symptoms can include chest pain, shortness of breath, persistent cough, weight loss and signs of enlarged lymph nodes. It usually will present in adults aged over 50 years old. 

Clinical worsening

For there to be an aggravation or situation involving clinical worsening, there needs to be clear progression of the condition out of keeping with the natural history expected of the underlying pathology.  Mesothelioma is usually associated with a poor prognosis and survival rate. Inability to obtain appropriate clinical management is unlikely to be relevant.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/mesothelioma-b005-c45/rulebase-mesothelioma/inability-obtain-appropriate-clinical-management-mesothelioma

Inhaling asbestos fibres

Current RMA Instruments:

Reasonable Hypothesis SOP

41 of 2024

Balance of Probabilities SOP

42 of 2024

Changes from Previous Instruments:

 

ICD coding:

Pleural (ICD-10 C45.0)

Pericardium (ICD-10 C45.2)

Peritoneum (ICD-10 C45.1)

Brief description:

Mesothelioma is a primary malignant neoplasm that is rare, aggressive and life-threatening. It is a cancer involving the mesothelial cells of the body, which line closed potential spaces of the body including the pleura (most common), pericardium, peritoneum and the tunica vaginalis of the testis.  

Confirming the diagnosis:

A biopsy of the malignancy is obtained with histological and immunochemical analysis undertaken to confirm this diagnosis. 

The relevant medical specialist is a medical oncologist or a respiratory physician.

Conditions not covered by these SOPs   

  • Soft tissue sarcoma*
  • Hodgkin’s lymphoma*
  • Non Hodgkin’s lymphoma*
  • Carcinoid tumour *

* another SOP applies  - the SOP has the same name unless otherwise specified

# non-SOP condition

Clinical onset

Assessing the date of clinical onset requires first confirming the established diagnosis via analysis of tissue samples and appropriate test results. The clinical date of onset can then be taken further back, if possible, to the first presentation of symptoms and signs consistent with the neoplasm. For example, if the case involves pleural mesothelioma, the symptoms can include chest pain, shortness of breath, persistent cough, weight loss and signs of enlarged lymph nodes. It usually will present in adults aged over 50 years old. 

Clinical worsening

For there to be an aggravation or situation involving clinical worsening, there needs to be clear progression of the condition out of keeping with the natural history expected of the underlying pathology.  Mesothelioma is usually associated with a poor prognosis and survival rate. Inability to obtain appropriate clinical management is unlikely to be relevant.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/mesothelioma-b005-c45/rulebase-mesothelioma/inhaling-asbestos-fibres

Inhaling erionite fibres

Current RMA Instruments:

Reasonable Hypothesis SOP

41 of 2024

Balance of Probabilities SOP

42 of 2024

Changes from Previous Instruments:

 

ICD coding:

Pleural (ICD-10 C45.0)

Pericardium (ICD-10 C45.2)

Peritoneum (ICD-10 C45.1)

Brief description:

Mesothelioma is a primary malignant neoplasm that is rare, aggressive and life-threatening. It is a cancer involving the mesothelial cells of the body, which line closed potential spaces of the body including the pleura (most common), pericardium, peritoneum and the tunica vaginalis of the testis.  

Confirming the diagnosis:

A biopsy of the malignancy is obtained with histological and immunochemical analysis undertaken to confirm this diagnosis. 

The relevant medical specialist is a medical oncologist or a respiratory physician.

Conditions not covered by these SOPs   

  • Soft tissue sarcoma*
  • Hodgkin’s lymphoma*
  • Non Hodgkin’s lymphoma*
  • Carcinoid tumour *

* another SOP applies  - the SOP has the same name unless otherwise specified

# non-SOP condition

Clinical onset

Assessing the date of clinical onset requires first confirming the established diagnosis via analysis of tissue samples and appropriate test results. The clinical date of onset can then be taken further back, if possible, to the first presentation of symptoms and signs consistent with the neoplasm. For example, if the case involves pleural mesothelioma, the symptoms can include chest pain, shortness of breath, persistent cough, weight loss and signs of enlarged lymph nodes. It usually will present in adults aged over 50 years old. 

Clinical worsening

For there to be an aggravation or situation involving clinical worsening, there needs to be clear progression of the condition out of keeping with the natural history expected of the underlying pathology.  Mesothelioma is usually associated with a poor prognosis and survival rate. Inability to obtain appropriate clinical management is unlikely to be relevant.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/mesothelioma-b005-c45/rulebase-mesothelioma/inhaling-erionite-fibres

Intravascular injection of thorium dioxide (Thorotrast)

Current RMA Instruments:

Reasonable Hypothesis SOP

41 of 2024

Balance of Probabilities SOP

42 of 2024

Changes from Previous Instruments:

 

ICD coding:

Pleural (ICD-10 C45.0)

Pericardium (ICD-10 C45.2)

Peritoneum (ICD-10 C45.1)

Brief description:

Mesothelioma is a primary malignant neoplasm that is rare, aggressive and life-threatening. It is a cancer involving the mesothelial cells of the body, which line closed potential spaces of the body including the pleura (most common), pericardium, peritoneum and the tunica vaginalis of the testis.  

Confirming the diagnosis:

A biopsy of the malignancy is obtained with histological and immunochemical analysis undertaken to confirm this diagnosis. 

The relevant medical specialist is a medical oncologist or a respiratory physician.

Conditions not covered by these SOPs   

  • Soft tissue sarcoma*
  • Hodgkin’s lymphoma*
  • Non Hodgkin’s lymphoma*
  • Carcinoid tumour *

* another SOP applies  - the SOP has the same name unless otherwise specified

# non-SOP condition

Clinical onset

Assessing the date of clinical onset requires first confirming the established diagnosis via analysis of tissue samples and appropriate test results. The clinical date of onset can then be taken further back, if possible, to the first presentation of symptoms and signs consistent with the neoplasm. For example, if the case involves pleural mesothelioma, the symptoms can include chest pain, shortness of breath, persistent cough, weight loss and signs of enlarged lymph nodes. It usually will present in adults aged over 50 years old. 

Clinical worsening

For there to be an aggravation or situation involving clinical worsening, there needs to be clear progression of the condition out of keeping with the natural history expected of the underlying pathology.  Mesothelioma is usually associated with a poor prognosis and survival rate. Inability to obtain appropriate clinical management is unlikely to be relevant.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/mesothelioma-b005-c45/rulebase-mesothelioma/intravascular-injection-thorium-dioxide-thorotrast